comparemela.com

Latest Breaking News On - Jiafu ji - Page 1 : comparemela.com

Combo Therapy Prolongs Survival in Gastric Cancer Patients

The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.

United-states
China
Peking
Beijing
Chinese
American
Jiafu-ji
American-association-for-cancer-research
Drug-administration
Institute-for-cancer-research
University-cancer-hospital
American-association

Cadonilimab Plus Chemo "Could Be New Standard Care" for Advanced Gastric, GEJ Cancer

Phase 3 data suggest that adding cadonilimab to chemotherapy can improve outcomes in patients with advanced gastric/GEJ cancer.

China
Beijing
Jiafu-ji
United-family-healthcare

Cadomilimab Plus Oxaliplatin and Capecitabine Leads to Survival Benefit in Gastric/GEJ Cancer

Cadomilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.

San-diego
California
United-states
Peking
Beijing
China
Jiafu-ji
University-hospital
China-national-medical-products-administration
Akeso-inc
Peking-university-hospital
Enrollment-criteria

AACR: Cadonilimab plus chemo beneficial for gastric adenocarcinoma

AACR: Cadonilimab plus chemo beneficial for gastric adenocarcinoma
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Peking
Beijing
China
United-states
San-diego
California
American
Jiafu-ji
American-association-for-cancer-research
American-association
Cancer-research
Gastrointestinal-cancer-center

Novel Treatment Shows Early Promise for Gastric Cancer

A novel antibody acting on both PD-1 and CTLA4 has shown activity in first-line treatment of gastric and gastroesophageal junction cancer.

Beijing
China
Peking
Chinese
Akeso-biopharma
Jiafu-ji
Katherine-bever
Johns-hopkins-university
University-cancer-hospital
Institute-gastrointestinal-cancer-center
Cancers-symposium
Peking-university-cancer-hospital

vimarsana © 2020. All Rights Reserved.